Listing of the Intermediate Capital Group (LON: ICP) share reaffirmed by Citigroup Inc. Minimum 3% coupon with capital protection based on Russell
Intermediate capital group (LON: ICP)Citigroup Inc. stock reiterated its “buy” rating by stock analysts at Citigroup Inc. 3% Russell-based minimum coupon protected in a report released Thursday, Analyst Rating Network reports. They currently have a GBX 2,534 ($ 33.11) price target on the stock. Citigroup Inc. A minimum 3% capital protected coupon based on Russell’s target price indicates a potential increase of 19.81% from the current price of the company.
Several other research analysts also recently commented on the headline. Shore Capital reiterated a “custody” note on Intermediate Capital Group shares in a report released Wednesday. Barclays increased its price target on Intermediate Capital Group shares from 1,570 GBX ($ 20.51) to 2,145 GBX ($ 28.02) and rated the stock “overweight” in a report published Tuesday, June 1. Finally, JPMorgan Chase & Co. lowered its price target on Intermediate Capital Group shares from 2,560 GBX ($ 33.45) to 2,400 GBX ($ 31.36) and set an “overweight” rating. for the company in a report released on Friday, June 11. Two equity research analysts gave the stock a conservation rating and four gave the company a buy rating. Intermediate Capital Group currently has a consensus rating of “Buy” and a consensus price target of 2,050.20 GBX ($ 26.79).
LON ICP traded lower GBX 78 ($ 1.02) on Thursday, reaching 2,115 GBX ($ 27.63). 922,195 shares were traded, for an average volume of 511,855. The company has a current ratio of 1.57, a quick ratio of 1.47 and a debt ratio of 91.23. Intermediate Capital Group has a 52-week minimum of GBX 1,128 ($ 14.74) and a 52-week maximum of GBX 2,355 ($ 30.77). The company has a market capitalization of £ 6.15 billion and a P / E ratio of 13.43. The company has a 50-day simple moving average of 2,095.32 GBX.
Separately, insider Antje Hensel-Roth sold 6,756 shares of the company in a trade that took place on Tuesday, June 8. The shares were sold for an average price of 2,280 GBX ($ 29.79), for a total deal of £ 154,036.80 ($ 201,250.07). In addition, Abersoch insider Davies acquired 1,997 shares of Intermediate Capital Group in a transaction dated Thursday, March 25. The shares were purchased at an average price of 1,884 GBX ($ 24.61) per share, for a total value of £ 37,623.48 ($ 49 15.32).
About Intermediate Capital Group
Intermediate Capital Group plc is a private equity firm specializing in direct investments and funds of funds. Within direct, she specializes in private debt, credit and equity investments. It invests in the middle, mature market, growth capital, reinvestment, industry consolidations, bridge financing, restructuring of a shareholder base, acquisitions, public-private transactions with or without financing. private equity, leveraged and acquisition financing, leveraged credit, partnership capital, management of corporate buyouts and buyouts, secondary investments, development capital, financing of listed companies , off-balance sheet financing, refinancing and recapitalization, pre-IPO financing.
See also: retirement calculator
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured article: Understanding the compound annual growth rate (CAGR)
7 health actions serving innovation in 2021
We all knew that traditional health services were disrupted in 2020. The patient-doctor relationship has gone virtual. During the first months of the pandemic, many people in need of elective surgeries simply did not have this option available to them. And even local pharmacies have taken on a new role in e-commerce as curbside pickup or home delivery of prescription drugs has become the norm.
It’s no surprise that healthcare stocks were beaten last year. Overall, the sector was down 11%, well below the S&P 500 which climbed more than 15%.
However, the market is always looking to the future with a particular eye on innovation. The healthcare sector has many companies that are developing innovative approaches in areas such as gene editing. And other companies are in advanced testing for drugs that can deliver groundbreaking results for conditions that continue to plague our world.
This is the object of this presentation. We have identified 7 healthcare actions that offer innovative ideas that will help achieve better patient outcomes. And in some cases, it will completely revolutionize medicine. These are also the stocks that analysts watch.
Consult the “7 healthcare stocks for innovation in 2021”.